Sally Roufail

The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.

Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens.

Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.

Vascular endothelial growth factor D is dispensable for development of the lymphatic system.

Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2.

Molecular pathways for lymphangiogenesis and their role in human disease.

The VD1 neutralizing antibody to vascular endothelial growth factor-D: binding epitope and relationship to receptor binding.

Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer.

Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies.

VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium.

The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.

Vascular endothelial growth factor-d modulates caliber and function of initial lymphatics in the dermis.

Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.

Vegf-d promotes pulmonary oedema in hyperoxic acute lung injury.